Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Screening and lead-in observational study for future AAV gene therapy eligibility in haemophilia B
NL-OMON54928Withdrawn
- Sponsor
- Freeline Therapeutics
- Start
- Apr 2021
- Countries
- 1
01
Overview
Open-label, single-arm trial in hemophilia B (HB), sponsored by Freeline Therapeutics. Primary endpoints: Bleeding episodes during prospective data capture and Factor IX concentrate consumption during prospective data capture. Planned start Apr 2021; status: withdrawn.
02
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON54928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54928.